Pharma’s Words Of Wisdom For Prospective Biotech Partners

Low Prices Not Changed The Foundations Of Dealmaking

09 Nov 2022

Stay patient and concentrate on building trust rather than the bank balance was one of the key pieces of advice offered by business development heads at Regeneron and Eli Lilly to start-ups attending the recent BIO-Europe meeting.

BIO Leipzig — There were over 4,000 attendees at BIO-Europe • Source: Kevin Grogan

A return to sensible valuations has helped increase the number of pacts between pharma and biotechs but experienced dealmakers from the bigger players have stressed that price is not the main driver when they go looking for partnerships.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

30 Apr 2025

• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

30 Apr 2025

• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.